Safety of injectable semaglutide for type 2 diabetes.
Rajesh PeterStephen C BainPublished in: Expert opinion on drug safety (2020)
Semaglutide is the most powerful injectable GLP-1RA. The cardiovascular (CV) outcome trial (SUSTAIN 6) showed CV superiority and its adverse event profile is as expected for the GLP-1RA class with predominantly gastrointestinal side-effects. Concerns about the thyroid and pancreatic safety have not been substantiated. There is no indication of renal or liver harm for semaglutide. Data consistent with reno-protection and benefit in liver disease is presented. There is a modest signal for increased gall bladder adverse events. An increase in diabetic retinopathy (DR) events in the SUSTAIN 6 trial is the most concerning safety signal. Caution regarding DR is needed when initiating semaglutide and recommendations are suggested.
Keyphrases
- diabetic retinopathy
- type diabetes
- rheumatoid arthritis
- study protocol
- clinical trial
- phase iii
- optical coherence tomography
- phase ii
- spinal cord injury
- disease activity
- randomized controlled trial
- editorial comment
- hyaluronic acid
- cardiovascular disease
- ankylosing spondylitis
- insulin resistance
- systemic lupus erythematosus
- machine learning
- big data
- weight loss
- idiopathic pulmonary fibrosis
- african american
- deep learning
- drug induced